<i>Candida pseudohaemulonii</i> Sp. Nov., an Amphotericin B‐ and Azole‐Resistant Yeast Species, Isolated from the Blood of a Patient from Thailand

Sugita, Takashi; Takashima, Masako; Poonwan, Natteewan; Mekha, Nanthawan

doi:10.1111/j.1348-0421.2006.tb03816.x

Cited by 48 publications

(59 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This trend can already be seen in the fact that 30 Candida species have already been found to cause human diseases. From the current study and others (1,2,13,15,29,38,39,41), it is clear that these numbers are expanding drastically by the use of molecular methods that improve the identification of existing and novel Candida species. a Results were compared with the standard dilution testing (CLSI) and three commercial test systems, Etest, Vitek 2, and Micronaut.…”

Section: Discussionmentioning

confidence: 77%

“…Thirty species of this genus have already been shown to cause diseases in humans (1,2,13,15,29,38,39,41,42), whereas the substantial progress in medical research and the increasing number of immunocompromised patients will increase the number of medically important Candida species in the future. Furthermore, these numbers are expanding by the introduction of molecular methods that improve the identification of existing and novel Candida species and offer the possibility of distinguishing strains of closely related species that were previously believed to belong to the same species (1,2,13,15,29,38,39,41).…”

mentioning

confidence: 99%

See 1 more Smart Citation

A Novel Flucytosine-Resistant Yeast Species, Candida pseudoaaseri, Causes Disease in a Cancer Patient

Pfüller¹,

Gräser

Erhard

et al. 2011

J Clin Microbiol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 77%

mentioning

confidence: 99%

A Novel Flucytosine-Resistant Yeast Species, Candida pseudoaaseri, Causes Disease in a Cancer Patient

Pfüller¹,

Gräser

Erhard

et al. 2011

J Clin Microbiol

View full text Add to dashboard Cite

show abstract

“…Although rarely isolated in clinical microbiology laboratories, C. haemulonii and C. pseudohaemulonii have consistently been reported to be resistant to AMB (7,8,18,20). We evaluated the ability of five antifungal susceptibility testing methods to detect AMB resistance in vitro in clinical isolates of C. haemulonii and C. pseudohaemulonii in comparison with C. auris, which is an unusual Candida species most closely related to C. haemulonii.…”

Section: Resultsmentioning

confidence: 99%

Detection of Amphotericin B Resistance in Candida haemulonii and Closely Related Species by Use of the Etest, Vitek-2 Yeast Susceptibility System, and CLSI and EUCAST Broth Microdilution Methods

et al. 2012

View full text Add to dashboard Cite

cThe emerging fungal pathogens Candida haemulonii and Candida pseudohaemulonii often show high-level resistance to amphotericin B (AMB). We compared the utilities of five antifungal susceptibility testing methods, i.e., the Etest using Mueller-Hinton agar supplemented with glucose and methylene blue (Etest-MH), the Etest using RPMI agar supplemented with glucose (Etest-RPG), the Vitek-2 yeast susceptibility system, and the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution methods, for the detection of AMB-resistant isolates of C. haemulonii and closely related species. Thirty-eight clinical isolates (8 C. haemulonii, 10 C. pseudohaemulonii, and 20 Candida auris isolates) were analyzed. Of the 18 C. haemulonii and C. pseudohaemulonii isolates, 18, 15, 18, 10, and 9 exhibited AMB MICs of >1 g/ml by the Etest-MH, Etest-RPG, Vitek-2, CLSI, and EUCAST methods, respectively. All 20 C. auris isolates showed AMB MICs of <1 g/ml by all five methods. Of the methods, the Etest-MH generated the broadest distribution of AMB MICs for all 38 isolates and showed the best discrimination between the C. haemulonii and C. pseudohaemulonii isolates (4 to 32 g/ml) and those of C. auris (0.125 to 0.5 g/ml). Taking the Etest-MH as the reference method, the essential agreements (within two dilutions) for the Etest-RPG, Vitek-2, CLSI, and EUCAST methods were 84, 92, 55, and 55%, respectively; the categorical agreements were 92, 92, 79, and 76%, respectively. This study provides the first data on the efficacy of the Etest-MH and its excellent agreement with Vitek-2 for discriminating AMB-resistant from AMB-susceptible isolates of these Candida species.

show abstract

“…Among the opportunistic non-C. albicans Candida species, C. glabrata, C. krusei, C. lusitaniae, and C. rugosa are well-known species that may exhibit innate or acquired resistance to one or more established antifungal agents (32). An amphotericin B-and azoleresistant species, C. pseudohaemulonii, isolated from the blood of a patient was reported recently (37). C. rugosa, the closest relative of the new species, is an emerging recognized opportunistic pathogen for humans.…”

Section: Discussionmentioning

confidence: 99%

Candida pseudorugosa sp. nov., a Novel Yeast Species from Sputum

Bai

2006

J Clin Microbiol

View full text Add to dashboard Cite

Two yeast strains, strains XH 1026 and XH 1164, isolated from the sputum of an intensive care unit patient with acute pneumonia, were originally identified as Candida albicans and C. tropicalis, respectively. Sequence analysis of the 26S rRNA gene D1/D2 domain and the internal transcribed spacer (ITS) region indicated that the two strains represent a novel yeast species closely related to C. rogusa. The name Candida pseudorugosa sp. nov. is therefore proposed (type strain, AS 2.3107 [CBS 10433]). The new species is able to grow at 42°C and is resistant or insusceptible to amphotericin B (MIC, 2 g/ml), caspofungin (MIC, 64 g/ml), itraconazole (MIC, 1 g/ml), and nystatin (MIC, 16 g/ml); dose-dependent susceptible to fluconazole (MIC, 16 g/ml); and susceptible to flucytosine (MIC, 0.125 g/ml) and voriconazole (MIC, 0.125 to 0.25 g/ml). The code for C. pseudorugosa sp. nov. provided by the API 20C AUX system is identical to that for C. rugosa. The colonies of the new species on CHROMagar Candida appear blue-green, similar to those of C. albicans. In addition to the molecular method based on D1/D2 domain or ITS region sequencing, use of the combination of the API system and CHROMagar Candida is helpful for the correct identification of C. pseudorugosa sp. nov.

show abstract

Candida pseudohaemulonii Sp. Nov., an Amphotericin B‐ and Azole‐Resistant Yeast Species, Isolated from the Blood of a Patient from Thailand

Cited by 48 publications

References 17 publications

A Novel Flucytosine-Resistant Yeast Species, Candida pseudoaaseri, Causes Disease in a Cancer Patient

A Novel Flucytosine-Resistant Yeast Species, Candida pseudoaaseri, Causes Disease in a Cancer Patient

Detection of Amphotericin B Resistance in Candida haemulonii and Closely Related Species by Use of the Etest, Vitek-2 Yeast Susceptibility System, and CLSI and EUCAST Broth Microdilution Methods

Candida pseudorugosa sp. nov., a Novel Yeast Species from Sputum

Contact Info

Product

Resources

About